Tillkännagivande • Jun 23
Centene Corporation Appoints Lauren M. Tyler to the Board of Directors, Effective June 19, 2026, and to Audit Committee and Compensation and Talent Committee, Effective July 1, 2026 Centene Corporation announced the appointment of Lauren M. Tyler to its Board of Directors, effective June 19, 2026. Ms. Tyler will serve on the Audit Committee and Compensation and Talent Committee, effective as of July 1, 2026. Ms. Tyler brings more than 30 years of leadership experience across investment banking, private equity, corporate audit, investor relations, and human capital strategy. Ms. Tyler spent over two decades at JPMorgan Chase & Co., where she held senior roles including Executive Vice President and Global Head of Human Resources for Asset and Wealth Management, Global Firmwide Chief Auditor, and Global Head of Investor Relations. Earlier in her career, she held roles at TSG Capital Partners, Allen & Company, and Morgan Stanley. She currently serves on the boards of Cencora Inc., and Guardian Life. She previously served on the board of Alleghany Corporation until its acquisition in 2022. Ms. Tyler holds an MBA from Harvard Business School and a BA from Yale University. Recent Insider Transactions • Jun 14
Director recently sold Mex$90m worth of stock On the 10th of June, Kenneth Burdick sold around 80k shares on-market at roughly Mex$1,122 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of Mex$123m more than they bought in the last 12 months. Tillkännagivande • Apr 30
Centene Corporation Updates Earnings Guidance for the Year 2026 Centene Corporation updated earnings guidance for the year 2026. For the year, the Company increased 2026 GAAP Diluted EPS Guidance to greater than $2.37. The company expects total revenue from $187.5 billion to $191.5 billion. Reported Earnings • Apr 28
First quarter 2026 earnings released: EPS: US$3.13 (vs US$2.64 in 1Q 2025) First quarter 2026 results: EPS: US$3.13 (up from US$2.64 in 1Q 2025). Revenue: US$49.9b (up 16% from 1Q 2025). Net income: US$1.54b (up 18% from 1Q 2025). Profit margin: 3.1% (up from 3.0% in 1Q 2025). Revenue is forecast to grow 3.4% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Healthcare industry in South America. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 69 percentage points per year, which is a significant difference in performance. Tillkännagivande • Apr 07
Centene Corporation Announces New Executive Appointments Centene Corporation announced the creation of two new executive leadership positions, which will report to Chief Executive Officer Sarah London. Centene has hired Daniel Finke as Group President, Markets and Commercial, and appointed Michael Carson to Group President, Medicare and Specialty. Finke, a seasoned healthcare executive with more than two decades of experience leading and scaling complex health plan organizations across government and commercial markets, will oversee the Medicaid and Commercial segments. He joins Centene from Convey Health Solutions, where he served as Chief Executive Officer. Prior to joining Convey, he was Executive Vice President of CVS Health and President of Aetna, leading strategy and operations spanning Medicare, Medicaid, and Commercial insurance businesses. As Group President, Medicare and Specialty, Michael Carson will have expanded oversight of Centene's Medicare Advantage, Medicare Part D, Duals, and Specialty businesses. Carson's experience spans nearly three decades of healthcare leadership. Prior to joining Centene in January 2024 as CEO of its Medicare business, Wellcare, Carson served as Chief Executive Officer for Bright Healthcare and Harvard Pilgrim Health Care, as well as CareAbout, a multi-specialty, value-based care delivery organization. Tillkännagivande • Mar 27
Centene Corporation, Annual General Meeting, May 12, 2026 Centene Corporation, Annual General Meeting, May 12, 2026. Location: centene plaza, 7700 forsyth boulevard, st. louis, missouri 63105, centene auditorium, United States Tillkännagivande • Mar 25
Centene Corporation Announces Executive Changes, Effective March 18, 2026 Centene Corporation announced that effective March 18, 2026, the Board of Directors appointed Theodore Pienkos, age 44, a registered CPA, to serve as the Company's Corporate Controller and Chief Accounting Officer. Mr. Pienkos previously has served as the Company's Deputy Corporate Controller since August 2024. Prior to that, he served as Vice President of Finance & Accounting from August 2017 to August 2024, and he has held other accounting roles of increasing importance with Centene since March 2011. Before joining Centene, Mr. Pienkos served as an auditor for KPMG LLP from August 2004 to March 2011. He holds a BA and MA in Accounting from the University of Northern Iowa. Centene Corporation also announced that Kate Casso, who has been with the Company for over two decades and served as the Company's prior Corporate Controller and Chief Accounting Officer since April 2021, has been appointed Senior Vice President, Finance Operations and Innovation, effective as of March 18, 2026. In this role, Ms. Casso will devote part of her time to innovation, both enterprise-wide and within Finance, while continuing to lead Data Analytics, Medical Economics, Payment Integrity, Finance Shared Services, Financial Planning and Analysis, and other various Finance teams. Reported Earnings • Feb 07
Full year 2025 earnings released: US$13.53 loss per share (vs US$6.33 profit in FY 2024) Full year 2025 results: US$13.53 loss per share (down from US$6.33 profit in FY 2024). Revenue: US$176.2b (up 20% from FY 2024). Net loss: US$6.67b (down 302% from profit in FY 2024). Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Healthcare industry in South America. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. Tillkännagivande • Feb 07
An undisclosed buyer signed a definitive agreement to acquire an unknown minority stake in Magellan Health, Inc. from Centene Corporation (NYSE:CNC). An undisclosed buyer signed a definitive agreement to acquire an unknown minority stake in Magellan Health, Inc. from Centene Corporation (NYSE:CNC) in December, 2025. Tillkännagivande • Feb 06
Centene Corporation Provides Earnings Guidance for the Fiscal Year Ending December 31, 2026 Centene Corporation provided earnings guidance for the fiscal year ending December 31, 2026. The Company expects its 2026 GAAP diluted EPS guidance of greater than $1.98 and Total revenues of $186.5 billion to $190.5 billion. Recent Insider Transactions • Dec 09
Director recently sold Mex$47m worth of stock On the 4th of December, Kenneth Burdick sold around 66k shares on-market at roughly Mex$712 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought Mex$7.5m more than they sold in the last 12 months. Recent Insider Transactions • Dec 07
Director recently sold Mex$47m worth of stock On the 4th of December, Kenneth Burdick sold around 66k shares on-market at roughly Mex$712 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Despite this recent sale, insiders have collectively bought Mex$7.5m more than they sold in the last 12 months. Board Change • Dec 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 1 highly experienced director. Independent Director Ken Tanji was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Nov 07
Centene Corporation's Ambetter from Arizona Complete Health Offers Health Insurance in Arizona in 2026 Centene Corporation's Ambetter from Arizona Complete Health will offer a variety of affordable health insurance plans to Arizonans in nine counties for plan year 2026. The open enrollment period for the Health Insurance Marketplace runs from Nov. 1, 2025, through Jan. 15, 2026. Enroll by Dec. 15, 2025, for coverage starting Jan. 1, 2026. Ambetter Health Solutions: Ambetter Health Solutions, Centene Corporation's off-exchange marketplace business offerings, delivers individual health insurance plans that are compatible with Individual Coverage Health Reimbursement Arrangements (ICHRAs). While not an ICHRA itself, Ambetter Health Solutions supports employers who choose to adopt this reimbursement model by providing employees with access to affordable, customizable and dependable coverage options. Available in select states, including Arizona, these plans empower individuals to choose the coverage that best fits their needs, helping employers control costs while offering greater choice and flexibility to their workforce. Ambetter Perks: Ambetter from Arizona Complete Health offers additional services to support health and financial well-being through the Ambetter Perks program for members in Arizona. This program gives members access to discounts on a variety of products and services, including wellness activities, financial tools, memberships, out-of-pocket prescription costs and over-the-counter (OTC) health items. It also includes services that promote healthy lifestyles and address social factors that impact health. The Ambetter Perks program is open to all members. Convenient Online Enrollment: Through the Ambetter from Arizona Complete Health website, people can browse and compare coverage options, determine their eligibility for financial subsidies and directly enroll in coverage -- all in one place. The platform is accessible through mobile devices, so people can enroll using smartphones. If a person is unable to complete enrollment all at once, the system will save progress and provide reminders to finish enrollment. My Health Pays: Members have access to the My Health Pays®? program, where they can earn points for practicing healthy eating habits, staying active and leading a healthy lifestyle. Through the program, members can complete health-related activities and challenges to earn up to $500 in rewards in 2026. These rewards can be used for health-related expenses such as copays and deductibles (pharmacy copays are excluded). My Health Pays also allows members to set and reach health goals at their own pace by providing seasonal suggestions for activities and guidance to help stay on track. Virtual 24/7 Care: Virtual 24/7 Care offers members a licensed provider via telehealth for members to access care for illnesses such as flu, skin conditions, ear infections, fever and respiratory infections -- all from the comfort of their home. Tillkännagivande • Oct 31
Centene Corporation Reports Impairment Charges for the Third Quarter 2025 Centene Corporation reported impairment charges for the third quarter 2025. For the quarter, the company reported non-cash goodwill impairment charge of $6.7 billion. Reported Earnings • Oct 31
Third quarter 2025 earnings released: US$13.50 loss per share (vs US$1.37 profit in 3Q 2024) Third quarter 2025 results: US$13.50 loss per share (down from US$1.37 profit in 3Q 2024). Revenue: US$49.7b (up 33% from 3Q 2024). Net loss: US$6.63b (down US$7.34b from profit in 3Q 2024). Revenue is forecast to grow 1.7% p.a. on average during the next 3 years, compared to a 9.1% growth forecast for the Healthcare industry in South America. Over the last 3 years on average, earnings per share has fallen by 22% per year whereas the company’s share price has fallen by 25% per year. Tillkännagivande • Oct 29
Centene Corporation Updates Earnings Guidance for the Full Year 2025 Centene Corporation updated earnings guidance for the full year 2025. The Company is updating its full year 2025 GAAP forecast to a diluted loss per share not to exceed $12.85. Tillkännagivande • Sep 29
Centene Corporation to Report Q3, 2025 Results on Oct 29, 2025 Centene Corporation announced that they will report Q3, 2025 results at 6:00 AM, US Eastern Standard Time on Oct 29, 2025 Valuation Update With 7 Day Price Move • Sep 11
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to Mex$633, the stock trades at a forward P/E ratio of 29x. Average forward P/E is 11x in the Healthcare industry in South America. Total loss to shareholders of 65% over the past three years. Recent Insider Transactions • Aug 15
CEO & Director recently bought Mex$9.1m worth of stock On the 8th of August, Sarah London bought around 19k shares on-market at roughly Mex$473 per share. This transaction amounted to 8.2% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Sarah has been a buyer over the last 12 months, purchasing a net total of Mex$14m worth in shares. Recent Insider Transactions • Aug 12
CEO & Director recently bought Mex$9.1m worth of stock On the 8th of August, Sarah London bought around 19k shares on-market at roughly Mex$473 per share. This transaction amounted to 8.2% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Sarah has been a buyer over the last 12 months, purchasing a net total of Mex$14m worth in shares. Tillkännagivande • Aug 07
Centene Corporation Stock Drop Triggers Securities Fraud Class Action Bleichmar Fonti & Auld LLP announced that a lawsuit has been filed against Centene Corporation and certain of the Company’s senior executives for potential violations of the federal securities laws. Investors have until September 8, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Centene securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned: Lunstrum v. Centene Corporation, et al., No. 25-cv-05659. Centene is a healthcare company that focuses on providing services to consumers enrolled in government-sponsored healthcare programs like Medicaid and Medicare, as well as those that purchase insurance under the Affordable Care Act from the Health Insurance Marketplace. On December 12, 2024, Centene announced financial guidance for fiscal year 2025 which the company said reflected “[s]tability in earnings power in the face of unprecedented headwinds.” Next, on February 4, 2025, Centene increased its 2025 guidance due to enrollment “overperformance.” Then, on April 25, 2025, Centene again increased 2025 guidance due to continued strong growth in enrollment and retention, while touting the “progress we are making as an organization while navigating a dynamic policy landscape.” In truth, the majority of the market that Centene serves was experiencing lower than expected enrollment growth and increased morbidity rates, or frequency of disease and illness. On July 1, 2025, Centene abruptly withdrew its previous guidance after reviewing an independent actuarial report from Wakely Consulting Group which showed that overall market growth in 22 of the 29 states Centene serves was lower than expected and that morbidity in those states was significantly higher than expected. On this news, the price of Centene stock fell $22.87 per share, or more than 40%, from $56.65 per share on July 1, 2025 to $33.78 per share on July 2, 2025. Recent Insider Transactions • Jul 30
Independent Director recently bought Mex$4.7m worth of stock On the 28th of July, Theodore Samuels bought around 9k shares on-market at roughly Mex$517 per share. This transaction amounted to 24% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought Mex$71m more in shares than they have sold in the last 12 months. New Risk • Jul 26
New minor risk - Profit margin trend The company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 1.2% Last year net profit margin: 2.0% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Shares are highly illiquid. Minor Risk Profit margins are more than 30% lower than last year (1.2% net profit margin). Valuation Update With 7 Day Price Move • Jul 08
Investor sentiment deteriorates as stock falls 43% After last week's 43% share price decline to Mex$606, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 10x in the Healthcare industry in South America. Total loss to shareholders of 63% over the past three years. Tillkännagivande • Jul 02
Centene Corporation to Report Q2, 2025 Results on Jul 25, 2025 Centene Corporation announced that they will report Q2, 2025 results on Jul 25, 2025 Reported Earnings • Apr 28
First quarter 2025 earnings released: EPS: US$2.64 (vs US$2.17 in 1Q 2024) First quarter 2025 results: EPS: US$2.64 (up from US$2.17 in 1Q 2024). Revenue: US$42.9b (up 17% from 1Q 2024). Net income: US$1.31b (up 13% from 1Q 2024). Profit margin: 3.1% (down from 3.2% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Healthcare industry in South America. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Tillkännagivande • Apr 25
Centene Corporation Re-Iterates Earnings Guidance for the Full Year 2025 Centene Corporation re-iterated earnings guidance for the full year 2025. For the year, the company expects increasing its 2025 premium and service revenues guidance range by $6.0 billion to a range of $164.0 billion to $166.0 billion to reflect the following expectations: $5.0 billion of additional Marketplace premium revenue due to outperformance in enrollment throughout the first quarter; and outperformance in the Medicare Advantage annual enrollment period resulting in $1.0 billion of additional premium revenue. The Company reiterates its 2025 GAAP diluted EPS guidance floor of greater than $6.1. Tillkännagivande • Mar 28
Centene Corporation, Annual General Meeting, May 13, 2025 Centene Corporation, Annual General Meeting, May 13, 2025. Location: centene plaza, 7700 forsyth blvd, missouri 63105, st.louis United States Tillkännagivande • Feb 25
Centene Corporation Appoints Kenneth Y. Tanji to Board of Directors and Member of Audit and Compliance Committee Centene Corporation announced the appointment of Kenneth Y. Tanji to the Centene Board of Directors, effective February 20, 2025. Mr. Tanji will serve on the Company's Audit and Compliance Committee. The appointment of Mr. Tanji expands Centene's Board of Directors to 12 members. Mr. Tanji's finance acumen spans more than three decades and includes deep knowledge of capital optimization strategies, strategic acquisitions, JV partnership models and the use of advanced analytics and technologies to scale growth. Mr. Tanji most recently served as Executive Vice President and Chief Financial Officer of Prudential Financial Inc. from 2018 to 2024. From 1988 to 2018, he held numerous leadership roles across Prudential's insurance, health insurance, annuities, and investment management businesses. Mr. Tanji currently serves on the Board of The Public Service Enterprise Group Inc. He is also a Corporate Finance professor at Rutgers University. Reported Earnings • Feb 20
Full year 2024 earnings released: EPS: US$6.33 (vs US$4.97 in FY 2023) Full year 2024 results: EPS: US$6.33 (up from US$4.97 in FY 2023). Revenue: US$147.2b (up 4.2% from FY 2023). Net income: US$3.31b (up 22% from FY 2023). Profit margin: 2.2% (up from 1.9% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.4% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Healthcare industry in South America. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings. Reported Earnings • Feb 05
Full year 2024 earnings released: EPS: US$6.33 (vs US$4.97 in FY 2023) Full year 2024 results: EPS: US$6.33 (up from US$4.97 in FY 2023). Revenue: US$147.3b (up 4.3% from FY 2023). Net income: US$3.31b (up 22% from FY 2023). Profit margin: 2.2% (up from 1.9% in FY 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Healthcare industry in South America. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. Tillkännagivande • Feb 05
Centene Corporation to Report Q1, 2025 Results on Apr 25, 2025 Centene Corporation announced that they will report Q1, 2025 results at 8:30 AM, Eastern Daylight on Apr 25, 2025 Tillkännagivande • Feb 04
Centene Corporation Reiterates Earnings Guidance for the Year 2025 Centene Corporation reiterated earnings guidance for the year 2025. The company reiterated its 2025 GAAP diluted EPS guidance floor of greater than $6.19 and its 2025 adjusted diluted EPS guidance floor of greater than $7.25. Board Change • Jan 29
High number of new directors Director Tom Greco was the last director to join the board, commencing their role in 2024. Board Change • Jan 16
High number of new directors Director Tom Greco was the last director to join the board, commencing their role in 2024. Tillkännagivande • Jan 09
Centene Corporation Names Alan Silver as the President of Its Ambetter Health Solutions Business Centene Corporation announced that Alan Silver has joined the organization as the President of its Ambetter Health Solutions business, which focuses on ICHRA (Individual Coverage Health Reimbursement Arrangements). This newly created role reflects Centene's belief that consumers increasingly will seek health insurance that offers transparency, customization, choice and convenience. ICHRA plans allow employees to shop on the individual Marketplace and choose the insurance plan that works best for them, using a tax-free stipend from their employer. Silver will bring more than two decades of leadership experience in benefits administration and actuarial consulting to the role, including a proven record of driving growth, developing client-focused benefit solutions and pioneering exchange-based healthcare strategies. Most recently, Silver led retiree medical and ICHRA initiatives at Willis Towers Watson. His expertise uniquely positions him to lead Ambetter's efforts in expanding and enhancing ICHRA offerings to meet and drive evolving market needs. Board Change • Dec 26
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Director Tom Greco was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Dec 16
Centene Corporation to Report Fiscal Year 2024 Results on Feb 04, 2025 Centene Corporation announced that they will report fiscal year 2024 results at 6:00 AM, US Eastern Standard Time on Feb 04, 2025 Tillkännagivande • Dec 13
Centene Corporation Provides Earnings Guidance for the Fiscal Year 2025 Centene Corporation provided earnings guidance for the fiscal year 2025. The Company expects its 2025 GAAP diluted EPS guidance of greater than$6.19 and Total revenues of $166.5 billion to $169.5 billion. Recent Insider Transactions • Nov 10
CEO & Director recently bought Mex$5.0m worth of stock On the 8th of November, Sarah London bought around 4k shares on-market at roughly Mex$1,223 per share. This transaction amounted to 2.4% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Sarah's only on-market trade for the last 12 months. Reported Earnings • Oct 26
Third quarter 2024 earnings released: EPS: US$1.37 (vs US$0.87 in 3Q 2023) Third quarter 2024 results: EPS: US$1.37 (up from US$0.87 in 3Q 2023). Revenue: US$37.3b (up 6.1% from 3Q 2023). Net income: US$713.0m (up 52% from 3Q 2023). Profit margin: 1.9% (up from 1.3% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 9.3% growth forecast for the Healthcare industry in South America. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Tillkännagivande • Oct 26
Centene Corporation Provides Earnings Guidance for the Year 2024 Centene Corporation provided earnings guidance for the year 2024. The Company is updating its 2024 GAAP diluted EPS guidance floor to greater than $5.92. Total revenues to be in the range of $159 billion to $161 billion. Board Change • Oct 24
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Director Tom Greco was the last director to join the board, commencing their role in 2024. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Oct 08
Centene Corporation to Report Q3, 2024 Results on Oct 25, 2024 Centene Corporation announced that they will report Q3, 2024 results at 6:00 AM, US Eastern Standard Time on Oct 25, 2024 Tillkännagivande • Oct 04
Ambetter Health of Delaware Offers Health Insurance in Delaware in 2025 Ambetter Health of Delaware, a product offered by a Centene Corporation company, which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, will offer Delawareans a variety of affordable health insurance plans in plan year 2025. Open enrollment for the Health Insurance Marketplace for Delaware runs from Nov. 1, 2024, through Dec. 15, 2024, for coverage starting Jan. 1, 2025. Enroll by Dec. 15, 2024, for coverage starting Jan. 1, 2025. Ambetter Health of Delaware offers its members access to quality care, convenient services and valuable rewards. The 2025 benefits and offerings include: Affordable and Reliable Coverage: Ambetter Health of Delaware provides coverage for all essential health benefits, including preventive and wellness services, maternity and newborn care, pediatric services, mental health services, hospitalizations and prescription drug coverage. Some plans also include dental and vision coverage. Virtual 24/7 Care: Virtual 24/7 Care offers members an Ambetter-designated licensed provider via telehealth for members to access care for illnesses such as flu, skin conditions, ear infections, fever and respiratory infections – all from the comfort of their own home. Convenient Online Enrollment: Through the Ambetter Health of Delaware website, people can browse and compare coverage options, determine their eligibility for financial subsidies and directly enroll in coverage – all in one place. The platform is accessible through mobile devices, so people can enroll using smartphones. If a person is unable to complete enrollment all at once, the system will save progress and provide reminders to finish enrollment. My Health Pays: Members have access to the My Health Pays program, where they can earn points for practicing healthy eating habits, staying active and leading a healthy lifestyle. Through the program, members can complete health-related activities and challenges and can earn up to $500 in rewards in 2025. These rewards can be used for health-related expenses such as premiums, copays and deductibles (pharmacy copays are excluded). My Health Pays® also allows members to set and reach health goals at their own pace by providing seasonal suggestions for activities and guidance to help stay on track. Premier Network: Beginning Jan. 1, 2025, the Ambetter Health Bronze|Silver|Gold network will become known as the Premier Network. Members can continue to rely on the same provider network with the doctors and hospitals they know and trust. Ambetter Health of Delawarewill be offered in New Castle, Kent and Sussex counties in 2025. Board Change • Sep 28
High number of new directors There are 5 new directors who have joined the board in the last 3 years. Independent Director Monte Ford was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Aug 16
Centene Corporation Announces the Election of Thomas R. Greco to Board of Directors Centene Corporation announced that it has appointed Thomas R. Greco to the Centene Board of Directors, effective August 9, 2024. Mr. Greco's term will run through the Company's 2025 annual meeting of stockholders. The appointment of Mr. Greco expands Centene's Board of Directors to 11 members. Mr. Greco is a seasoned operator and executive who brings more than four decades of public company leadership and expertise to Centene. Over the course of his career, he has implemented growth strategies and fostered talent development and diversity for consumer-focused companies. He most recently served as President and Chief Executive Officer (CEO) of Advance Auto Parts Inc., a Raleigh-based automotive parts retailer, from 2016 to 2023. Prior to his tenure at Advance Auto Parts, Mr. Greco spent three decades in roles of increasing responsibility at PepsiCo before becoming CEO of Frito-Lay North America in 2011. Mr. Greco currently serves on the boards of Tapestry Inc., a publicly traded, multinational fashion company, the Sabra Dipping Company LLC, a joint venture between PepsiCo and the Strauss Group, and the American Heart Association. A longtime advocate for cardiovascular health, Mr. Greco has been actively involved in several initiatives aimed at enhancing the nutritional profile of consumer products throughout his career. Reported Earnings • Jul 28
Second quarter 2024 earnings released: EPS: US$2.16 (vs US$1.93 in 2Q 2023) Second quarter 2024 results: EPS: US$2.16 (up from US$1.93 in 2Q 2023). Revenue: US$36.4b (up 3.6% from 2Q 2023). Net income: US$1.15b (up 8.3% from 2Q 2023). Profit margin: 3.1% (up from 3.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 9.0% growth forecast for the Healthcare industry in South America. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Board Change • Jul 26
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Independent Director Monte Ford was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Jul 04
Centene Corporation to Report Q2, 2024 Results on Jul 26, 2024 Centene Corporation announced that they will report Q2, 2024 results at 6:00 AM, US Eastern Standard Time on Jul 26, 2024 Reported Earnings • Apr 28
First quarter 2024 earnings released: EPS: US$2.17 (vs US$2.05 in 1Q 2023) First quarter 2024 results: EPS: US$2.17 (up from US$2.05 in 1Q 2023). Revenue: US$36.9b (up 4.5% from 1Q 2023). Net income: US$1.16b (up 2.9% from 1Q 2023). Profit margin: 3.2% (in line with 1Q 2023). Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Healthcare industry in South America. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Apr 27
Centene Corporation Updates Earnings Guidance for the Year 2024 Centene Corporation updated earnings guidance for the year 2024. For the year, the Company is updating its 2024 diluted EPS guidance floor to greater than $5.94. Total revenue is expected to be in range of $147.5 Billion to $150.5 Billion. Board Change • Apr 25
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Independent Director Monte Ford was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Mar 30
Centene Corporation, Annual General Meeting, May 14, 2024 Centene Corporation, Annual General Meeting, May 14, 2024, at 10:00 Central Standard Time. Location: Centene Plaza 7700 Forsyth Boulevard St. Louis, Missouri 63105 Centene Auditorium Missouri United States Agenda: To consider elect ten directors to hold office until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified; to discuss cast a non-binding advisory vote on the compensation of the Company's Named Executive Officers; to ratify the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to discuss Stockholder proposal. Tillkännagivande • Mar 08
Centene Corporation to Report Q1, 2024 Results on Apr 26, 2024 Centene Corporation announced that they will report Q1, 2024 results at 6:00 AM, US Eastern Standard Time on Apr 26, 2024 Reported Earnings • Feb 22
Full year 2023 earnings released: EPS: US$4.97 (vs US$2.09 in FY 2022) Full year 2023 results: EPS: US$4.97 (up from US$2.09 in FY 2022). Revenue: US$141.3b (up 3.9% from FY 2022). Net income: US$2.70b (up 125% from FY 2022). Profit margin: 1.9% (up from 0.9% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Healthcare industry in South America. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Recent Insider Transactions • Feb 11
President recently sold Mex$15m worth of stock On the 7th of February, Kenneth Fasola sold around 12k shares on-market at roughly Mex$1,279 per share. This transaction amounted to 18% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Kenneth's only on-market trade for the last 12 months. Reported Earnings • Feb 07
Full year 2023 earnings released: EPS: US$4.97 (vs US$2.09 in FY 2022) Full year 2023 results: EPS: US$4.97 (up from US$2.09 in FY 2022). Revenue: US$141.5b (up 4.0% from FY 2022). Net income: US$2.70b (up 125% from FY 2022). Profit margin: 1.9% (up from 0.9% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare industry in South America. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. Tillkännagivande • Feb 06
Centene Corporation Increases Premium and Service Revenues Guidance for the Fiscal Year 2024 Centene Corporation increased premium and service revenues guidance for the fiscal year 2024. for the year, the company increased premium and service revenues guidance range by $2.5 billion to a range of $134.5 billion to $137.5 billion to reflect additional Commercial premium revenue from a stronger than expected Marketplace open enrollment. Board Change • Jan 25
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Independent Director Monte Ford was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Jan 23
Centene Corporation Announces Appointment of Michael A. Carson as President and Chief Executive Officer of Its Medicare Business Centene Corporation announced two appointments. Michael A. Carson joins Centene as President and Chief Executive Officer of its Medicare business, Wellcare. Mr. Carson will be responsible for Medicare business performance, strategy and growth and will report to Centene President Ken Fasola. Carson succeeds Richard Fisher, who has been appointed to the Operations leadership team under Centene Chief Operating Officer Susan Smith. Mr. Fisher will have responsibility for key financial and operational processes across Shared Services, as well as lead enterprise development, management and optimization of Centene's key vendor partnerships. Mr. Carson brings nearly three decades of seasoned leadership, operational and industry expertise in both the payer and provider space with a deep focus on and expertise in serving Medicare and dual-eligible populations. As the CEO of value-based primary and multi-specialty care start-up CareAbout, he led a fully delegated, risk-bearing Medicare and dual-eligible-focused care delivery organization. Mr. Carson also served as the CEO of Bright Health Plan and as the President and CEO of Harvard Pilgrim Health Care. He led the formation and rebuilding of Medicare businesses at both Amerigroup and Anthem, as well as served in transformative leadership roles at ConcertoHealth and other Blue Cross Blue Shield plans. Mr. Carson started his career in the United States Air Force, where he served for almost a decade before transitioning to corporate roles. Mr. Carson earned a Bachelor of Science in Business Administration from the University of Phoenix. He serves as Non-Executive Board Chair of HYKE, and as an Advisory Board Member of both Foodsmart and OneHealth. Tillkännagivande • Jan 13
Pure Health LLC completed the acquisition of Circle Health Group Limited from Centene Corporation (NYSE:CNC). Pure Health LLC agreed to acquire Circle Health Group Limited from Centene Corporation (NYSE:CNC) for an enterprise value of approximately $1.2 billion on August 28, 2023. The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the first quarter of 2024. Barclays is serving as financial advisor to Centene, and Dickson Minto is serving as its legal counsel. BofA Securities, Inc. acted as financial advisor to Pure Health LLC. Braeden Donnelly, Simon Rahimzada, Michel Sheng and Joshua Cole, Neil Cunninghame, Simon Swann, Mark Spinney, Bradley Rice, Rhiannon Webster, Sunny Kumar, Eleanor Reeves, Henry Moss, John Gordo and Briony Holcombe of Ashurst LLP and Ashurst, Dubai acted as Legal advisor to Pure Health LLC
Pure Health LLC completed the acquisition of Circle Health Group Limited from Centene Corporation (NYSE:CNC) on January 12, 2024. Tillkännagivande • Dec 13
Centene Corporation to Report Fiscal Year 2023 Results on Feb 06, 2024 Centene Corporation announced that they will report fiscal year 2023 results at 6:00 AM, US Eastern Standard Time on Feb 06, 2024 Tillkännagivande • Dec 12
Centene Corporation Provides Earnings Guidance for the Fiscal Year 2024 Centene Corporation provided earnings guidance for the fiscal year 2024. For the year, the company expected total revenues of $142.5 billion to $145.5 billion. GAAP diluted earnings per share (EPS) of greater than $5.61. Board Change • Nov 29
High number of new directors There are 6 new directors who have joined the board in the last 3 years. Independent Director Monte Ford was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Tillkännagivande • Nov 17
Centene Corporation Announces the Appointment of Susan Smith as Chief Operating Officer, Effective January 1, 2024 Centene Corporation announced the appointment of Susan Smith as its Chief Operating Officer (COO), effective January 1, 2024. As COO, Ms. Smith will report to Centene President Ken Fasola and will be responsible for core business operations, population health, the enterprise transformation office, provider experience and quality. She has worked at Centene since June 2023.Ms. Smith brings nearly two decades of expertise in the payer space, having spent 19 years at Humana. She most recently served as SVP of Clinical, Quality and Enterprise Solutions President, where she had oversight of quality; clinical strategy, analytics and product development; clinical operations; risk adjustment; and experience transformation. Prior to this role, Ms. Smith served as SVP of Clinical Solutions and SVP of Medicare. Among numerous accomplishments during her tenure, she is credited for her work in leading Humana's efforts to improve its Star ratings and member quality; in playing a central role in the design and development of Medicaid operations for Humana; and for her experienced leadership creating sustainable organizations and processes during transformative times. She held other leadership roles, including SVP of Healthcare Quality Reporting and Improvement, and Vice President of Risk Adjustment, among others. Ms. Smith started her career at Colgate-Palmolive. Ms. Smith earned a Bachelor of Science in Chemical Engineering and a Master of Engineering in Chemical Engineering -- both from the University of Louisville Speed Scientific School. Reported Earnings • Oct 25
Third quarter 2023 earnings released: EPS: US$0.87 (vs US$1.29 in 3Q 2022) Third quarter 2023 results: EPS: US$0.87 (down from US$1.29 in 3Q 2022). Revenue: US$35.2b (up 2.2% from 3Q 2022). Net income: US$469.0m (down 36% from 3Q 2022). Profit margin: 1.3% (down from 2.1% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare industry in South America. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. 
